USPTO Form [illegible] Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.	Serial No.
18396/2282	10/775,679
Applicant(s):. Friedler, et al.	
Filing Date: February 10, 2004	Group: ~~Unknown~~ 1653

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
AR	1.	WO97/37645	October 16, 1997	WO	A61K	31/135		
	2.	WO99/58566	Nov 18, 1999	WO	C07K	14/47		
	3.	WO00/32175	June 8, 2000	WO	A61K	31/00		
	4.	DE100 43 456 A1	March 14, 2002	DE	A61K	31/505	See 4A	
	4A.	US2003/0199446 A1	October 23, 2003	US	A61K	38/17		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

AR	5.	Foster, et al., "Pharmacological Rescue of Mutant p53 Conformation and Function", *Science*, V. 286, December 24, 1999, Pages 2507-2510.
	6.	Gamble, et al., "Evidence that Immunological Variants of p53 Represent Alternative Protein Conformations", *Virology* (1988), V. 162, Pages 452-458.
	7.	Naumovski, et al., "The p53-Binding Protein 53BP2 Also Interacts with Bc12 and Impedes Cell Cycle Progression at G_2/M", *Molecular and Cellular Biology*, V. 16, July 7, 1996, Pages 3884-3892.
	8.	Nikolova, et al, "Mechanism of Rescue of Common p53 Cancer Mutations by Second-Site Suppressor Mutations", *The Embo Journal* (2000), V. 19, No. 3, Pages 370-378.
	9.	Selivanova, et al., "Reactivation of Mutant p53 Through Interaction of a C-Terminal Peptide with the Core Domain", *Molecular and Cellular Biology*, V. 19, No. 5, May 1999, Pages 3395-3402.
	10.	Copy of the International Search Report (PCT/GB02/03668)

EXAMINER	DATE CONSIDERED
Agnes B. Rooke	3/16/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.	Serial No.
18396/2282	10/775,679

Applicant(s):. Friedler, et al.

Filing Date: February 10, 2004 | Group: ~~Not yet assigned~~ 1653

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES	Translation NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

AR	1.	Cho, et al., "Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations", Science (1994), V. 265, Pages 346-355.
	2.	Selivanova, et al., "Restoration of the growth suppression function of mutant *p53* by a synthetic peptide derived from the p53 C-terminal domain", Nature Medicine (1997), V. 3, Pages 632-638.
	3.	Bullock, et al., "Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy", Oncogene (2000), V. 19, Pages 1245-1256.
	4.	Abarzua, et al., "Restoration of the transcription activation function to mutant p53 in human cancer cells", Oncogene (1996), V. 13, Pages 2477-2482.
	5.	Hainaut, et al., "p53 and human cancer: the first ten thousand mutations", Advances in Cancer Research (2000), V. 77, Pages 81-137.
	6.	Hupp, et al., "Small peptides activate the latent sequence-specific DNA binding function of p53", Cell (1995), V. 83, Pages 237-245.
	7.	Hupp, et al., "Strategies for manipulating the p53 pathway in the treatment of human cancer", Biochemical Journal (2000), V. 352, Pages 1-17.
	8.	Sigal, et al., "Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome", Cancer Research (2000), V. 60, Pages 6788-6793.
↓	9.	Selivanova, et al., "Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain", Molecular and Cellular Biology (1999), V. 19, Pages 3395-3402.

EXAMINER Agnes B. Rooke | DATE CONSIDERED 3/16/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.